SHANGHAI and WUXI, China, Sept. 22,
2016 /PRNewswire/ -- WuXi Biologics, a leading
open-access R&D capability and technology platform company
dedicated to biologics and a WuXi AppTec company, announced today
the opening of a new commercial-scale cGMP biologics perfusion
manufacturing facility in Wuxi city, China.
In April 2015 WuXi Biologics
announced plans to build a $150
million commercial biologics manufacturing facility in Wuxi
city. The first phase of construction is complete and commences
operation today after 17 months. The new facility accommodates two
1000L disposable bioreactors for perfusion processes and is the
largest perfusion biologics manufacturing facility to date in
Asia implementing disposable
bioreactors.
This added capacity will support WuXi's robust biologics
commercial manufacturing pipeline and enable WuXi to maintain its
position as the premier biologics manufacturer in China as well as a leader worldwide. The new
commercial biologics manufacturing facility will also address the
needs of Chinese companies as Marketing Authorization Holder (MAH)
system is currently being piloted.
"The opening of the new commercial manufacturing facility marks
another milestone for WuXi," said Dr. Ge
Li, Chairman and CEO of WuXi AppTec, "We will uphold the highest quality standards
to expedite global development of biologics for both international
and domestic clients."
"This new facility further strengthens WuXi Biologics'
capabilities in integrated biologics discovery, development, and
manufacturing services," said Dr. Chris
Chen, CEO of WuXi Biologics, "WuXi Biologics is committed to
providing a seamless, truly ONE-stop service for our partners and
clients from concept to commercialization. "
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical,
biopharmaceutical, and medical device open-access capability and
technology platform company with global operations. As an
innovation-driven and customer-focused company, WuXi AppTec
provides a broad and integrated portfolio of services to help our
worldwide customers and partners shorten the discovery and
development time and lower the cost of drug and medical device
R&D through cost-effective and efficient solutions. With its
industry-leading capabilities in small molecule R&D and
manufacturing, biologics R&D and manufacturing, cell therapy
and gene therapy R&D and manufacturing, medical device testing,
and molecular testing and genomics, WuXi platform is enabling more
than 2,000 innovative collaborators from more than 30 countries to
bring innovative healthcare products to patients, and to fulfill
WuXi's dream that "every drug can be made and every disease can be
treated." Please visit http://www.wuxiapptec.com.
About WuXi Biologics
WuXi Biologics, a WuXiAppTec company, is a leading open-access
technology capability and technology platform to enable anyone and
any company to develop biologics. As a premier Contract Discovery,
Development and Manufacturing Organization (CDMO), WuXi Biologics
provides our worldwide clients with the necessary expertise,
quality and capacities to develop biologic drugs from concept to
commercialization. Along with our WuXiAppTec affiliates, we provide
the world with the ONE true single-source approach that saves our
clients critical time and money. Our company history and
achievements demonstrate our commitment to providing a truly
ONE-stop service offering and value proposition to our global
clients. For more information on WuXi's Biologics services, please
visit: http://www.wuxibiologics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-biologics-completes-construction-of-asias-largest-perfusion-biologics-manufacturing-facility-using-disposable-bioreactors-300332389.html
SOURCE WuXi AppTec